DK1906928T3 - Kerner og mikrokapsler egnet til parenteral administration og fremgangsmåder til fremstilling deraf - Google Patents

Kerner og mikrokapsler egnet til parenteral administration og fremgangsmåder til fremstilling deraf

Info

Publication number
DK1906928T3
DK1906928T3 DK06743048T DK06743048T DK1906928T3 DK 1906928 T3 DK1906928 T3 DK 1906928T3 DK 06743048 T DK06743048 T DK 06743048T DK 06743048 T DK06743048 T DK 06743048T DK 1906928 T3 DK1906928 T3 DK 1906928T3
Authority
DK
Denmark
Prior art keywords
nuclei
preparation
methods
microcapsules
parenteral administration
Prior art date
Application number
DK06743048T
Other languages
English (en)
Inventor
Nils Ove Gustafsson
Monica Joensson
Timo Laakso
Original Assignee
Stratosphere Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stratosphere Pharma Ab filed Critical Stratosphere Pharma Ab
Application granted granted Critical
Publication of DK1906928T3 publication Critical patent/DK1906928T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
DK06743048T 2005-05-27 2006-05-24 Kerner og mikrokapsler egnet til parenteral administration og fremgangsmåder til fremstilling deraf DK1906928T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011516 2005-05-27
EP05028165A EP1726299A3 (en) 2005-05-27 2005-12-22 Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
PCT/EP2006/004940 WO2006125620A2 (en) 2005-05-27 2006-05-24 Cores and microcapsules suitable for parenteral administration as well as process for their manufacture

Publications (1)

Publication Number Publication Date
DK1906928T3 true DK1906928T3 (da) 2009-04-20

Family

ID=36935013

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06743048T DK1906928T3 (da) 2005-05-27 2006-05-24 Kerner og mikrokapsler egnet til parenteral administration og fremgangsmåder til fremstilling deraf

Country Status (7)

Country Link
EP (2) EP1726299A3 (da)
JP (1) JP5080453B2 (da)
AT (1) ATE424190T1 (da)
CA (1) CA2609891A1 (da)
DE (1) DE602006005491D1 (da)
DK (1) DK1906928T3 (da)
WO (1) WO2006125620A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
GB0707612D0 (en) 2007-04-19 2007-05-30 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
US20090022808A1 (en) * 2007-05-23 2009-01-22 Allergan, Inc. Coated Hyaluronic Acid Particles
WO2008147867A2 (en) 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
WO2009065116A1 (en) 2007-11-16 2009-05-22 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
ES2829971T3 (es) 2008-09-02 2021-06-02 Tautona Group Lp Hilos de ácido hialurónico y/o derivados de los mismos, métodos para fabricar los mismos y usos de los mismos
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CA2792729C (en) 2010-03-12 2016-06-28 Allergan Industrie, Sas Fluid compositions for improving skin conditions
EP3078388B1 (en) 2010-03-22 2019-02-20 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
KR102238406B1 (ko) 2011-06-03 2021-04-08 알러간 인더스트리 에스에이에스 항산화제를 포함하는 피부 충전제 조성물
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
WO1992016191A1 (en) * 1991-03-25 1992-10-01 Fujisawa Pharmaceutical Co., Ltd. Long-acting pharmaceutical preparation
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
SE505146C2 (sv) 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
AU747211B2 (en) * 1997-07-18 2002-05-09 Bayer Corporation Methods of removing residual solvent from nasal drug delivery compositions
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
CN1309737C (zh) * 1999-11-12 2007-04-11 法布罗根股份有限公司 重组明胶
JP2004510845A (ja) 2000-10-06 2004-04-08 ヤゴテック　アーゲー 製薬上許容される澱粉
CA2424896A1 (en) * 2000-10-06 2002-04-11 Jagotec Ag A controlled-release, parenterally administrable microparticle preparation
CA2424936A1 (en) 2000-10-06 2002-04-11 Jagotec Ag Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

Also Published As

Publication number Publication date
EP1726299A2 (en) 2006-11-29
JP5080453B2 (ja) 2012-11-21
JP2008542220A (ja) 2008-11-27
DE602006005491D1 (de) 2009-04-16
ATE424190T1 (de) 2009-03-15
EP1906928A2 (en) 2008-04-09
WO2006125620A2 (en) 2006-11-30
WO2006125620A3 (en) 2007-08-02
EP1726299A3 (en) 2007-04-18
CA2609891A1 (en) 2006-11-30
EP1906928B1 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
DK1906928T3 (da) Kerner og mikrokapsler egnet til parenteral administration og fremgangsmåder til fremstilling deraf
ATE444746T1 (de) Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen
ATE482194T1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
IS2582B (is) Afleiður af N-(arýlsúlfónýl)beta-amínósýrum sem samanstanda af setnum amínómetýl hópi, aðferð til framleiðslu á afleiðum og lyfjafræðilegar samsetningar sem innihalda þær
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
AR052238A1 (es) Formulacion de tabletas estables
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DE502007002772D1 (de) Neue mit cyclohexylresten substituierte1,4-benzothiepin-1,1 -dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
ATE501114T1 (de) Herstellung von 3-pentennitril aus 1,3-butadien
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
DE602006019732D1 (de) Indolylmaleimidderivate
SE0401762D0 (sv) Novel compounds
DE602005002647D1 (de) Hexensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
EP2586427A3 (en) Balsalazide formulations and manufacture thereof
BRPI0518786A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
BRPI0518790A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete
ATE372992T1 (de) Indanyl-piperazinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
DK1742927T3 (da) Butanonsyrederivater, fremgangsmåder til fremstilling deraf, farmaceutiske præparater omfattende dem, og farmaceutiske applikationer deraf
NO20076120L (no) Stabile nanopartikkelformuleringer
CY2011018I1 (el) Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος
EA200801080A1 (ru) Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион